natgillin/translations-raw huggingface dataset:
In study UC-II, among those treated with Humira who were in remission at Week 8, 21/41 (51%) were in remission at Week 52.
V študiji UC-II je bilo 21/41 bolnikov (51 %), ki so bili zdravljeni z zdravilom Humira in so dosegli remisijo 8. teden, v remisiji 52. teden.
• If you are allergic to adalimumab or any of the other ingredients of this medicine (listed in section
• če ste alergični na adalimumab ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Humira has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see Section 5.1) and to improve physical function.
rentgenskim slikanjem je bilo dokazano, da zdravilo Humira upočasni hitrost napredovanja prizadetosti perifernih sklepov pri bolnikih s poliartikularno, simetrično podvrsto bolezni (glejte poglavje 5.1) in izboljša telesno funkcijo.
Table 28 Response, Remission and Mucosal Healing in Study UC-II (Percent of Patients) Placebo Humira 40 mg eow
Preglednica 28 Odziv, remisija in celjenje sluznice v študiji UC-II (odstotek bolnikov) Placebo Humira 40 mg vsak drugi teden
Available data suggest that re-introduction of Humira after discontinuation for 70 days or longer resulted in the same magnitudes of clinical response and similar safety profile as before dose interruption.
70 dni ali več, dosegla enako velik klinični odziv in je imela podobne varnostne značilnosti kot pred prekinitvijo.
• neuropathy (disorder of the nerves)
• nevropatija (okvara živcev)
Humira is used to treat polyarticular juvenile idiopathic arthritis in patients from 2 years of age.
Zdravilo Humira se uporablja za zdravljenje poliartikularnega juvenilnega idiopatskega artritisa pri bolnikih od 2. leta starosti.
At Week 4 patients were randomised to 40 mg every other week, 40 mg every week, or placebo with a total study duration of 56 weeks.
V 4. tednu so bili bolniki randomizirani na 40 mg vsak drugi teden, 40 mg vsak teden ali placebo celo trajanje študije 56 tednov.
In patients with moderately to severely active paediatric Crohn's disease, the rate of anti-adalimumab antibody development in patients receiving adalimumab was 3.3%.
Delež pediatričnih bolnikov z zmerno do hudo aktivno Crohnovo boleznijo pri bolnikih, ki so prejeli adalimumab in razvili protitelesa proti adalimumabu je bil 3,3 %.
• a bump or open sore that doesn't heal;
• bula ali odprta rana, ki se ne zaceli;
The safety and efficacy of multiple doses of Humira were assessed in adult patients with moderately to severely active ulcerative colitis (Mayo score 6 to 12 with endoscopy subscore of 2 to 3) in randomised, double-blind, placebo-controlled studies.
Varnost in učinkovitost večkratnih odmerkov zdravila Humira so ocenili pri odraslih z zmernim do hudo aktivnim ulceroznim kolitisom (ocena Mayo od 6 do 12 z endoskopsko podoceno 2 do 3) v randomiziranih, dvojno slepih, s placebom kontroliranih študijah.
Your doctor will decide if Humira should be used with methotrexate or alone.
Vaš zdravnik se bo odločil, ali naj se zdravilo Humira uporablja z metotreksatom ali samo.
• Vaccinations: if possible children should be up to date with all vaccinations before using Humira.
• Cepljenja: če je mogoče, naj vaš otrok pred začetkom uporabe zdravila Humira opravi vsa potrebna cepljenja.
Humira is recommended for use in combination with methotrexate.
Priporočljiva je uporaba zdravila Humira v kombinaciji z metotreksatom.
Children and adolescents from 6 to 17 years of age weighing 40 kg or more The usual dose regimen is 80 mg (as two 40 mg injections in one day) initially followed by 40 mg two weeks later.
Otroci in mladostniki, stari od 6 do 17 let, ki tehtajo 40 kg ali več Običajni začetni odmerek je 80 mg (dve 40 mg injekciji v enem dnevu), ki mu sledi 40 mg dva tedna kasneje.
Of 542 patients who were randomised to Humira 40 mg every other week, 170 patients continued on Humira 40 mg every other week for 10 years.
Od 542 bolnikov, ki so bili randomizirani na zdravilo Humira 40 mg vsak drugi teden, jih je 170 nadaljevalo zdravljenje z zdravilom Humira 40 mg vsak drugi teden še 10 let.
In RA studies I-IV, Humira-treated patients achieved statistically significant ACR 20 and 50 responses compared to placebo as early as one to two weeks after initiation of treatment.
V študijah revmatoidnega artritisa I-IV so z zdravilom Humira zdravljeni bolniki v primerjavi s prejemniki placeba dosegli statistično značilen odziv 20 in 50 po ACR že en do dva tedna po začetku zdravljenja.
 PASI 75
PASI 75 in
• moderate to severe hidradenitis suppurativa in adults and
• zmernega do hudega hidradenitis suppurativa pri odraslih in
All p-values are pairwise comparisons of proportions for Humira versus placebo p < 0.001 p < 0.01
Vse p-vrednosti so parne primerjave razmerja zdravila Humira proti placebu * p < 0,001 ** p < 0,01
With your free hand, gently grasp a sizable area of the cleaned skin at the injection site and hold firmly (see below).
S prosto roko obzirno primite očiščeni predel kože in ga trdno držite (glejte spodaj).
Patients were randomised to 40 mg of Humira or placebo every other week for 24 weeks.
Bolnike so randomizirali na 40 mg zdravila Humira ali placebo vsak drugi teden za 24 tednov.
• serious infections (including blood poisoning and influenza)
• resne okužbe (vključno z zastrupitvijo krvi in gripo)
In a study of 64 patients with rheumatoid arthritis that were treated with Humira, there was no evidence of depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in enumeration of effector T-, B-, NK-cells, monocyte/macrophages, and neutrophils.
V študiji 64 bolnikov z revmatoidnim artritisom, zdravljenih z zdravilom Humira, niso odkrili znakov zavrtja odložene preobčutljivosti, znižanja koncentracije imunoglobulinov ali spremembe števila efektorskih celic T in B, naravnih celic ubijalk, monocitov/makrofagov ali nevtrofilcev.
• Non-infectious uveitis
• neinfekcijskega uveitisa
You will then hear a loud ‘click' as the needle is released and you will feel a small prick as the needle advances.
Ko se bo igla sprožila, boste zaslišali glasen "klik", in ob njenem vbodu boste začutili droben bodljaj.
In patients with Crohn's disease, anti-adalimumab antibodies were identified in 7/269 subjects (2.6%) and in 19/487 subjects (3.9%) with ulcerative colitis.
Pri bolnikih s Crohnovo boleznijo so identificirali protitelesa proti adalimumabu pri 7 od 269 bolnikov (2,6 %) in pri 19 od 487 bolnikov (3,9 %) z ulceroznim kolitisom.
A greater proportion of patients on Humira had no disease flare during the double-blind period, when compared with those on placebo (70.4% vs. 47.1%, p<0.001) (Figure 1).
Pri večjem deležu bolnikov, ki so prejemali zdravilo Humira, v dvojno slepem obdobju ni prišlo do ponovnega zagona bolezni v primerjavi s tistimi, ki so prejemali placebo (70,4 % v primerjavi s 47,1 %, p < 0,001) (slika 1).
The Humira pre-filled syringe is available in a pack containing 2 pre-filled syringes with 2 alcohol pads.
Napolnjena injekcijska brizga zdravila Humira je na voljo v pakiranju, ki vsebuje 2 napolnjeni injekcijski brizgi z 2 alkoholnima zložencema.
Patients were then re-treated with adalimumab 0.8 mg/kg eow for an additional 16 weeks and response rates observed during retreatment were similar to the previous double-blind period: PASI 75 response of 78.9% (15 of 19 subjects) and PGA clear or minimal of 52.6% (10 of 19 subjects).
Bolniki so bili nato znova zdravljeni z adalimumabom v odmerku 0,8 mg/kg vsak drugi teden še nadaljnjih 16 tednov, pri čemer so bile opažene stopnje odziva podobne kot v prejšnjem dvojno slepem obdobju: odziv PASI 75 pri 78,9 % (15 od 19 oseb) in PGA čisto ali minimalno pri 52,6 % (10 od 19 oseb).
The safety and efficacy of Humira were assessed in over 1500 patients with moderately to severely active Crohn's disease (Crohn's Disease Activity Index (CDAI)  220 and  450) in randomised, double-blind, placebo-controlled studies.
Varnost in učinkovitost zdravila Humira so ovrednostili pri preko 1500 bolnikih z zmerno do hudo aktivno Crohnovo boleznijo (Crohn's Disease Activity Index (CDAI) ≥ 220 in ≤ 450) v randomizirani, dvojno slepi, s placebom kontrolirani študiji.
• heart problems that can cause shortness of breath or ankle swelling
• težave s srcem, ki lahko povzročijo kratko sapo ali otekanje gležnjev
DO NOT use if the liquid is cloudy, discoloured or has flakes or particles in it.
Zdravila NE UPORABLJAJTE, če je tekočina motna, obarvana ali vsebuje kosmiče ali delce.
Each new injection should be given at least 3 cm from the last injection site.
Vsako naslednjo injekcijo morate dati vsaj 3 cm od mesta prejšnje injekcije.
Humira is injected under the skin (subcutaneous use).
Zdravilo Humira se injicira pod kožo (subkutana uporaba).
Similar remission rates were observed for the 160/80 mg and 80/40 mg induction regimens by Week 8 and adverse events were more frequently noted in the 160/80 mg group.
Podobne stopnje remisije so opazili za 160/80 mg in 80/40 mg indukcijski režim v 8. tednu.
RA study I evaluated 271 patients with moderately to severely active rheumatoid arthritis who were  18 years old, had failed therapy with at least one disease-modifying, anti rheumatic drug and had insufficient efficacy with methotrexate at doses of 12.5 to 25 mg (10 mg if methotrexate-intolerant) every week and whose methotrexate dose remained constant at 10 to 25 mg every week.
V študiji revmatoidnega artritisa I je bilo ocenjeno 271 bolnikov z zmerno do hudo aktivnim revmatoidnim artritisom, starih ≥ 18 let, pri katerih zdravljenje z vsaj enim imunomodulirajočim antirevmatičnim zdravilom ni bilo uspešno, pri katerih metotreksat v odmerkih od 12,5 do 25 mg (10 mg, če so bili intolerantni za metotreksat) vsak teden ni bil dovolj učinkovit in pri katerih je odmerek metotreksata od 10 do 25 mg ostal stalen vsak teden.
You should not take Humira with medicines containing the active substances anakinra or abatacept due to increased risk of serious infection.
Zdravila Humira ne smete jemati z zdravili, ki vsebujejo učinkovini anakinro ali abatacept zaradi povečanega tveganja za resne okužbe.
Improvement in number of active joints with arthritis was maintained during the OL period through Week 156 for the 26 of 31 (84%) patients in the Humira group who remained in the study.
Izboljšanje v številu aktivnih sklepov z artritisom se je ohranilo v obdobju odprtega preskušanja po 156. tednu pri 26 od 31 (84 %) bolnikov, ki so ostali v študiji in ki so prejemali zdravilo Humira.
• Ankylosing spondylitis,
• ankilozirajoči spondilitis,
The symptoms described above can be signs of the below listed side effects, which have been observed with Humira.
Opisani simptomi so lahko znaki naslednjih neželenih učinkov, ugotovljenih med uporabo zdravila
Among patients who were at least partial responders at Week 12, and who received continuous weekly Humira therapy, the HiSCR rate at Week 48 was 68.3% and at Week 96 was 65.1%.
Pri bolnikih z vsaj delnim odzivom na zdravilo Humira v odmerku 40 mg v 12. tednu, in ki so prejemali neprekinjeno tedensko terapijo Humira vsak teden, je bila stopnja kliničnega odziva (HiSCR) v 48. tednu 68,3 % in v 96. tednu 65,1 %.
In adult patients with Crohn's disease, anti-adalimumab antibodies were identified in 7/269 subjects
Pri bolnikih s Crohnovo boleznijo so identificirali protitelesa proti adalimumabu pri 7 od 269 bolnikov
After 12 weeks of therapy, patients who had received Humira in Period A were re-randomised in Period B to 1 of 3 treatment groups (Humira 40 mg every week, Humira 40 mg every other week, or placebo from Week 12 to Week 35).
Po 12 tednih terapije so bolnike, ki so prejemali zdravilo Humira v obdobju A, ponovno randomizirali v obdobju B v eno izmed treh skupin zdravljenja (zdravilo Humira 40 mg vsak teden, zdravilo Humira 40 mg vsak drugi teden ali placebo od 12. do 35. tedna).
Leukopenia (including neutropenia and agranulocytosis), anaemia
zelo pogosti levkopenija (vključno z nevtropenijo in agranulocitozo), anemija
The safety and efficacy of Humira were assessed in a multicentre, randomised, double-blind study in 46 paediatric patients (6 to 17 years old) with moderate enthesitis-related arthritis.
Varnost in učinkovitost zdravila Humira so ocenili v multicentrični, randomizirani, dvojno slepi študiji pri 46 pediatričnih bolnikih (starih od 6 do 17 let) z zmernim artritisom, povezanim z entezitisom.
• nerve disorders (such as eye nerve inflammation and Guillain-Barré syndrome that may cause muscle weakness, abnormal sensations, tingling in the arms and upper body)
• bolezni živčevja (kot je vnetje očesnega živca in sindrom Guillain-Barré, ki lahko povzroči šibkost mišic, nenormalna občutenja, mravljinčenje v rokah in zgornjem delu telesa)
The white needle sleeve will now be exposed.
Zdaj je viden beli tulec igle.
• new onset or worsening of psoriasis
• izpadanje las • pojav ali poslabšanje psoriaze
Your child should not take Humira with medicines containing the active substances anakinra or abatacept due to increased risk of serious infection.
Zdravila Humira vaš otrok ne sme jemati z zdravili, ki vsebujejo učinkovini anakinro ali abatacept zaradi povečanega tveganja za resne okužbe.
Your doctor may recommend temporary discontinuation of Humira.
Vaš zdravnik bo morda priporočil začasno prenehanje uporabe zdravila Humira.
Do not remove the caps until just before injection.
Pokrovčke odstranite šele tik pred injiciranjem.
Keep this Patient Reminder Card with you.
To opozorilno kartico za bolnika imejte pri sebi.
The following instructions explain how to inject Humira.
Spodnja navodila pojasnjujejo, kako injicirati zdravilo Humira.
• lupus-like syndrome
• sindrom podoben lupusu
Humira has not been studied in patients with enthesitis-related arthritis aged less than 6 years.
Zdravila Humira niso preučevali pri bolnikih z artritisom, povezanim z entezitisom, starih manj kot 6 let.
• nerve disorders (such as eye nerve inflammation and Guillain-Barré syndrome that may cause muscle weakness, abnormal sensations, tingling in the arms and upper body);
• bolezni živčevja (kot je vnetje očesnega živca in sindrom Guillain-Barré, ki lahko povzroči šibkost mišic, nenormalna občutenja, mravljinčenje v rokah in zgornjem delu telesa);
RA study II evaluated 544 patients with moderately to severely active rheumatoid arthritis who were  18 years old and had failed therapy with at least one disease-modifying, anti-rheumatic drugs.
V študiji revmatoidnega artritisa II je bilo ocenjeno 544 bolnikov z zmerno do hudo aktivnim revmatoidnim artritisom, starih ≥ 18 let, pri katerih zdravljenje z vsaj enim imunomodulirajočim antirevmatičnim zdravilom ni bilo uspešno.
Amongst those who responded at Week 16 (n=144), the Pediatric ACR 30/50/70/90 responses were maintained for up to six years in the OLE phase in patients who received Humira throughout the study.
Med bolniki, ki so se odzvali 16. teden (n = 144), so se odzivi »Pediatric ACR« 30/50/70/90 v odprti podaljšani fazi ohranili do šest let pri tistih, ki so ves čas študije dobivali zdravilo Humira.
In patients not given concomitant methotrexate, the incidence was 12.4%, compared to 0.6% when adalimumab was used as add-on to methotrexate.
Pri bolnikih, ki sočasno niso dobivali metotreksata, je bila incidenca 12,4 %, pri tistih, ki so adalimumab uporabljali kot dodatek metotreksatu, pa 0,6 %.
The safety and efficacy of Humira were assessed in randomised, double-blind, placebo-controlled studies and an open-label extension study in adult patients with moderate to severe hidradenitis suppurativa (HS) who were intolerant, had a contraindication or an inadequate response to at least a 3-month trial of systemic antibiotic therapy.
Varnost in učinkovitost zdravila Humira so raziskali v randomiziranih, dvojno slepih študijah, kontroliranih s placebom in v odprti podaljšani študiji pri odraslih bolnikih z zmerno do hudo obliko hidradenitis suppurativa (HS), ki imajo intoleranco, kontraindikacijo ali se ne odzovejo zadovoljivo pri vsaj 3-mesečnem preskušanju sistemske antibiotične terapije.
Humira is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroidsparing, or in whom corticosteroid treatment is inappropriate.
Zdravilo Humira je indicirano za zdravljenje neinfekcijskega intermediarnega, posteriornega uveitisa in panuveitisa pri odraslih bolnikih, ki se niso zadostno odzvali na zdravljenje s kortikosteroidi, pri bolnikih s potrebo po zmanjšani uporabi kortikosteroidov ali pri bolnikih, pri katerih je zdravljenje s kortikosteroidi neprimerno.
Week 16 Placebo-Controlled
16. teden Kontrolirana s placebom26.
All patients should be advised to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias (e.g. persistent fever, bruising, bleeding, pallor) while on Humira.
Vsem bolnikom je treba naročiti, naj nemudoma poiščejo zdravniško pomoč, če se jim med uporabo zdravilaHumira pojavijo znaki ali simptomi krvnih diskrazij (npr. trajno zvišana telesna temperatura, podplutbe, krvavitve, bledica).
After 16 weeks of therapy, patients who achieved at least a PASI 75 response (PASI score improvement of at least 75% relative to baseline), entered period B and received open-label 40 mg Humira every other week.
Po 16 tednih zdravljenja so bolniki, ki so dosegli odziv PASI vsaj 75 (izboljšanje ocene PASI za vsaj 75 % glede na izhodišče), vstopili v obdobje B, med katerim so v odprti študiji dobivali 40 mg zdravila Humira vsak drugi teden.
leflunomide and injectable gold preparations)
hidroksiklorokinom, leflunomidom in pripravki zlata za injiciranje)
The incidence of serious infections was 0.04 per patient year in Humira treated patients and 0.03 per patient year in placebo and active control − treated patients.
Incidenca resnih okužb je bila 0,04 na bolnikov-let med bolniki, ki so dobivali zdravilo Humira, in 0,03 na bolnikov-let med bolniki, ki so dobivali placebo oziroma kontrolno učinkovino.
Pharmacotherapeutic group: Immunosuppressants, Tumour Necrosis Factor alpha (TNF-α) inhibitors.
Farmakoterapevtska skupina: Zdravila za zaviranje imunske odzivnosti, zaviralci tumorje nekrotizirajočega faktorja alfa (TNF-α), oznaka ATC: L04AB04.
Do not use this medicine after the expiry date stated on the label/blister/carton after EXP.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki/pretisnem omotu/škatli poleg oznake “Uporabno do”.
After treatment with Humira, a rapid decrease in levels of acute phase reactants of inflammation (C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)) and serum cytokines (IL-6) was observed, compared to baseline in patients with rheumatoid arthritis.
Po zdravljenju z zdravilom Humira so pri bolnikih z revmatoidnim artritisom opažali hitro znižanje reaktantov akutne faze vnetja (C-reaktivnega proteina (CRP) in hitrosti sedimentacije eritrocitov (SR)) in serumskih citokinov (IL-6) v primerjavi z izhodiščem.
Patients treated with Humira usually experienced improvement in haematological signs of chronic inflammation.
Z zdravilom Humira zdravljenim bolnikom so se ponavadi izboljšali hematološki znaki kroničnega vnetja.
You and your doctor should pay special attention to signs of infection while you are being treated with Humira.
Vi sami in vaš zdravnik morata biti posebej pozorna na znake okužbe, medtem ko ste zdravljeni z zdravilom Humira.
Humira has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.
Z rentgenskim slikanjem je bilo dokazano, da zdravilo Humira upočasni hitrost napredovanja prizadetosti sklepov in izboljša telesno funkcijo, kadar se uporablja v kombinaciji z metotreksatom.
Humira has not been studied in patients with hepatic or renal impairment.
Zdravila Humira niso proučili pri bolnikih z okvaro jeter ali ledvic.
PsA study I with 24 week duration, treated 313 adult patients who had an inadequate response to non-steroidal anti-inflammatory drug therapy and of these, approximately 50% were taking methotrexate.
V njej so zdravili 313 odraslih, ki se niso ustrezno odzvali na terapijo z nesteroidnimi protivnetnimi zdravili; približno 50 % od teh je jemalo metotreksat.
Hidradenitis suppurativa Age or body weight
Hidradenitis suppurativa Starost ali telesna masa
• facial oedema associated with allergic reactions;
• edem obraza povezan z alergijskimi reakcijami;
• Do not remove the Grey or Plum-coloured Caps while allowing Humira to reach room temperature
• Sivega ali škrlatnega pokrovčka ne odstranite dokler zdravilo Humira ne doseže sobne temperature.
Corticosteroids or other medicines that influence the immune system may be continued while using Humira.
Kortikosteroidi ali druga zdravila, ki zavirajo imunski sistem, se lahko še nadalje uporabljajo ob uporabi zdravila Humira.
Patients who had been randomised to placebo in Period A were assigned to receive Humira 40 mg every week in Period B.
Bolniki, ki so jih randomizirali na placebo v obdobju A, so v obdobju B prejemali zdravilo Humira 40 mg vsak teden.
The other ingredients are mannitol, polysorbate 80 and water for injections.
Druge sestavine zdravila so manitol, polisorbat 80 in voda za injekcije.
Lift the pre-filled pen straight up from the injection site.
Dvignite napolnjeni injekcijski peresnik navpično z mesta injiciranja.
Based on the observed data approach, 216 (80.3%) were in quiescence (no active inflammatory lesions, AC cell grade ≤ 0.5+, VH grade ≤ 0.5+) with a concomitant steroid dose ≤ 7.5 mg per day, and 178 (66.2%) were in steroid-free quiescence.
Na osnovi pristopa z opaženimi podatki je bilo 216 (80,3 %) bolnikov v remisiji (brez aktivnih vnetnih lezij, ocena celic sprednje očesne komore ≤ 0,5+, motnost steklovine ≤ 0,5+) ob sočasnem jemanju steroidov v odmerku ≤ 7,5 mg na dan in pa 178 bolnikov (66,2 %), ki so bili v remisiji in brez steroidov.
All patients received a 2-week standardised dose of prednisone 60 mg/day at study entry followed by a mandatory taper schedule, with complete corticosteroid discontinuation by Week 15.
Vsi bolniki so ob začetku študije prejeli 2-tedenski standardizirani odmerek prednizona 60 mg/dan, čemur je sledil obvezen program postopnega zmanjševanja, s popolno ukinitvijo kortikosteroidov do 15. tedna.
Administration of Humira should be discontinued if a patient develops a new serious infection or sepsis, and appropriate antimicrobial or antifungal therapy should be initiated until the infection is controlled.
Če se bolniku pojavi nova resna okužba ali sepsa, je treba uporabo zdravila Humira prekiniti in uvesti ustrezno protimikrobno ali protimikotično zdravljenje, dokler okužba ni obvladana.
The serum levels of free adalimumab (not bound to anti-adalimumab antibodies, AAA) were observed to be lower in patients with measurable AAA.
Ugotovljeno je bilo, da so koncentracije prostega adalimumaba (tistega, ki ni vezan na protitelesa proti adalimumabu) v serumu manjše pri bolnikih, ki imajo merljivo raven protiteles proti adalimumabu.
Very common
Skupno je bilo
Humira has been shown to slow down the damage to the cartilage and bone of the joints caused by the disease and to improve physical function.
Dokazano je, da zdravilo Humira upočasni okvaro sklepnega hrustanca in kosti, ki jo povzroča ta bolezen in izboljšuje telesno delovanje.
h MRI Sacroiliac Joints d,i
SPARCCh MRI sakroiliakalnih sklepov d,i
Exposure-response relationships between adalimumab concentration and efficacy in paediatric patients with severe chronic plaque psoriasis were established for PASI 75 and PGA clear or minimal, respectively.
Razmerji med izpostavljenostjo in odzivom med koncentracijo adalimumaba in učinkovitostjo pri pediatričnih bolnikih s hudo kronično psoriazo v plakih sta bili za PASI 75 (PASI - Psoriasis Area and
Contents of the pack and other information Injecting Humira
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Humira